NOVATO, CA, May 31, 2018 (GLOBE NEWSWIRE) -- Mount Tam Biotechnologies, Inc. ("Mount Tam" or the “Company”) (OTC
PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors, is pleased to announce that
stockholders holding a majority of the Company’s common stock voted to approve the following actions:
- Increase the number of authorized shares of common stock from 100,000,000 to 200,000,000; and
- Grant the Company’s board of directors the authority, in the reasonable discretion of the board, to effect a reverse stock
split within the next twelve months at a ratio to be determined by the board.
The Company believes that these actions allow for increased flexibility to focus on the key goal of increasing stockholder
value, whether through raising additional capital, uplisting, in-licensing or acquiring additional assets, or executing other
strategic transactions.
“We are grateful to our stockholders for their support,” said Mount Tam CEO Richard Marshak. “The increase in our
authorized shares improves the flexibility we have to use newly-authorized shares of our common stock to advance our corporate
goals. Further, the ability to execute a reverse stock split is an important step, should the board choose to take it,
towards fulfilling the minimum stock price requirement for listing the Company’s common stock to a senior stock exchange.”
Additional details surrounding these approvals are set forth in the Company’s SEC filings.
About Mount Tam Biotechnologies, Inc.
Mount Tam Biotechnologies was established to develop, optimize and bring to market novel pharmaceutical
products to improve the health and well-being of patients suffering from a range of serious disease states where there is
significant unmet need. Mount Tam is focused on the discovery and development of novel mTOR inhibitors, with specific emphasis
on developing compounds with unique mTORC1:mTORC2 inhibitory profiles. Mount Tam believes it has an industry leadership
position in developing therapeutic products which address aberrations in the mTOR pathway, and is confident that both TAM-01 and
TAM-03 are significantly differentiated from currently marketed rapalogs and have the potential to bring significant benefits to
patients.
Mount Tam has partnered with the world-renowned Buck Institute for Research on Aging through a worldwide exclusive licensing and
collaboration agreement. The licensed assets are highly target-specific polyketides. Mount Tam is advancing its lead asset,
TAM-01, toward an Investigational New Drug (IND) application with the FDA and has largely completed non-GLP pre-clinical
development. The lead indication for TAM-01 is expected to be the treatment of SLE. Mount Tam is also advancing follow-on
compounds through the discovery process and is looking at a broad range of disease areas where novel mTOR inhibitors have been
shown to have the potential to address unmet need.
For more information visit www.MountTamBiotech.com
Forward-Looking Statements:
The information disclosed in this press release is made as of the date hereof and reflects Mount Tam’s most current assessment
of its historical position and financial performance. Actual results may differ from those contained herein due to factors outside
of the control of Mount Tam. Additionally, this press release may contain certain forward-looking statements and information, as
defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and
is subject to the Safe Harbor created by those sections.
These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors
that could cause actual results to differ materially from those expressed in the forward-looking statements including, without
limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors
Mount Tam identifies from time to time in its filings with the SEC. Forward-looking statements are identified by wording such as
"scheduled (future sense)", "intend(s)", "plan(s)", "expect(s)", "believe(s)", "will", "estimate(s)", "anticipate(s)", "expect(s)",
"may", "would", "could" or "should" or, in each case, the negative thereof, other variations thereon, or comparable terminology
that implies anticipated future performance, timing of an IND application, or the results of any such application. Although
Mount Tam believes that the assumptions on which these forward-looking statements are based are reasonable, any of those
assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be
incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in
this release are made as of the date hereof, and Mount Tam disclaims any intention or obligation to update the forward-looking
statements for subsequent events.
Company Contact: Jim Stapleton Chief Financial Officer jim@mounttambiotech.com Phone: 425-214-4079
